Bristol Myers, Pfizer to sell blood thinner Eliquis directly to patients

Bristol Myers (BMY) and Pfizer (PFE) announced the launch of their 'Eliquis 360 Support' program on September 8, allowing cash-paying patients to directly purchase their blockbuster blood thinner Eliquis at over 40% below its current list price. This direct-to-patient sales initiative aims to provide significant savings and enhanced access for consumers, particularly for a drug that generated $11.4 billion in global revenue in 2024. The move represents a notable shift in pharmaceutical distribution, potentially bypassing traditional channels to directly engage patients.

Analysis

Bristol Myers Squibb (BMY) and Pfizer (PFE) are implementing a direct-to-patient sales program for their leading blood thinner, Eliquis, offering a discount of over 40% to cash-paying patients starting September 8. This strategic initiative targets a key product that generated approximately $11.4 billion in global revenue in 2024 and is the most prescribed oral anticoagulant in the U.S. By creating a direct sales channel, the companies are aiming to enhance patient access and affordability, a move that could bolster market share and patient retention. This represents a notable evolution in pharmaceutical distribution, potentially bypassing traditional intermediaries for a specific consumer segment. The neutral sentiment score of 0.5 for both tickers reflects investor uncertainty, weighing the positive public relations and potential volume defense against the margin impact from the significant price reduction on sales to cash-paying customers.

Key Decisions for Investors

• Investors should monitor post-September 8 sales data to assess whether the program successfully defends or grows Eliquis's total prescription volume against the backdrop of a significant revenue reduction per unit in the cash-pay segment.
• Consider the potential for margin compression on the highly profitable Eliquis franchise, as the financial impact will depend on the size of the cash-paying patient population that utilizes this program.
• View this as a potential test case for the broader pharmaceutical industry; similar moves by competitors could signal a systemic shift in drug pricing and distribution models, impacting the entire sector.
• Given the neutral market reaction, it may be prudent to await tangible data on patient uptake and the financial effects in subsequent quarterly reports before altering positions in BMY or PFE based solely on this announcement.